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Radiation proctitis is a known complication following radiation therapy for pelvic malignancy. The majority of cases are treated
nonsurgically, and an understanding of the available modalities is crucial in the management of these patients. In this paper, we
focus on the current treatments of radiation proctitis.
1.Introduction
Radiation causes both apoptosis and cell death secondary
to damage to DNA, proteins, and lipids and usually aﬀects
rapidly proliferating cells such as those found in cancer [1].
Today, radiation to the pelvis is an important constituent
in the treatment of pelvic malignancies and is administered
either as neoadjuvant or adjuvant therapy. Initially, radiation
therapy (RT) was believed to provide no beneﬁt for patients,
especially patients with rectal cancer, due to the resistance
of these cancers to radiation. Only later was it discovered
that higher doses were required to overcome that resistance.
However, higher doses of radiation have resulted in collateral
damage to organs in or surrounding the ﬁeld of radiation.
Currently, the most frequent complication of radiation ther-
apy, secondary to the utilization of higher doses, is proctitis
after treatment for prostate cancer [2].
Radiation therapy can be administered via external beam
radiation or radioactive implants termed brachytherapy. Ex-
ternalbeamradiationistypicallyadministeredbyanexternal
photon generator with a variety of sources including gamma
rays, electron beams, and X-rays via a four-beam approach
which results in signiﬁcant exposure to surrounding organs
[3].Particulartoprostatecancertreatment,certainregionsof
the rectum receive a dose similar to, if not equal to, the dose
delivered to the prostate. Newer modalities of external beam
ra d i a t i o nd e l i v e rya t t e m p tt od e l i v e re q u i v o c a lo rh i gh e rd o s -
es but with decreased toxicity to surrounding areas; these
modalities include three-dimensional conformal radiation
therapy (3D-CRT) [4] and intensity-modulated radiation
therapy (IMRT) [5]. 3D-CRT utilizes CT scanning to focus
radiation ﬁelds with a constant dose rate [4], while IMRT
utilizes computational methods for beam orientation and
dose adjustments within the same beam ﬁeld [5]. Both
methods allow for the use of higher doses of radiation for
t a r g e tt i s s u e sw i t hl e s se x p o s u r eo fn o r m a lt i s s u e .N e w e r
methods are currently being developed and tested, which
utilize heavy particles such as protons and neutrons, to im-
prove outcomes with reduced toxicity. These methods have
the potential to deliver optimal doses of radiation to the
target tissue with reduced damage to normal adjacent tissue;
long-term outcomes are not clear, and these techniques
currently come at signiﬁcantly higher cost [3].
Brachytherapy has two methods of delivery that attempt
toachievethesamegoaloflocalizedexposureoftargettissue.
The most common approach necessitates the implantation
of radioactive pellets (typically iodine 125 or palladium
103) into the target tissue with a gradual release over
time [6]. An alternative method involves the use of hollow
catheters that can be progressively ﬁlled with increasing
amounts of radioactive pellets over time. Brachytherapy re-
duces exposure damage to surrounding tissue based on care-
ful positioning of the implanted pellets [6] .T h er a t eo f
colorectal complications with brachytherapy is generally
lower compared to external beam radiation. A study by
Lesperance et al. show a decrease for both acute (6% versus2 Gastroenterology Research and Practice
43%) and chronic (2% versus 21%) complications with
brachytherapy when compared to external beam radiation
[7, 8].
Theincidenceofradiationproctitisisnotclearduetothe
lack of consensus on its deﬁnition and reporting method-
ologies. There is a general agreement that the incidence is
likelyrelatedtothedoseofradiation,areaofexposure,meth-
odofdelivery,andtheuseofcytoprotectiveagents.Thedoses
generally delivered to the pelvis vary from 45 to 50Gy for
adjuvant or neoadjuvant treatment for prostate or anorectal
malignancies;upto90Gyisconsideredthedeﬁnitivetherapy
for gynecological malignancies [9, 10]. It is generally agreed
that treatments <45Gy cause very few side eﬀects. Doses
between 45 and 70Gy, which is the dosage range for most
treatments,causemorecomplications,butthecomplications
tend to be of lesser intensity [9, 10]. Doses above 70Gy cause
signiﬁcant and long standing injury to the surrounding area
[9, 10]. The Radiation Therapy Oncology Group (RTOG)
and the European Organization for Research and Treatment
of Cancer (EORTC) individually attempted to classify the
degree of radiation proctitis into a graded system of symp-
toms progressing from no symptoms to fatal complications
(Table 1)[ 11, 12]. External beam radiation studies have
seen incidence rates of radiation proctitis range from 2% to
39% [7–10] depending upon the severity/grade of proctitis,
whereas IMRT studies have seen incidence rates from 1% to
9% [11–13] and particle radiation therapy in the range of
1% [14]. Although particle radiation therapy seems to have
a lower incidence of proctitis, it is limited by cost and only
available at specialized facilities. The incidence of proctitis in
patients treated with brachytherapy alone is 8% to 13% and
up to 21% when used in combination with other modalities
[15].
Radiation proctitis is generally classiﬁed as acute or
chronic, usually delineated by the timeframe of symptoms in
relation to the treatment as well as the presenting symptoms
and signs.
2. AcuteProctitis
Acute radiation proctitis is deﬁned as an inﬂammatory
process involving only the superﬁcial mucosa [2] that occurs
almost immediately after the initiation of therapy or up to
3 months after the onset of therapy [16]. Symptoms includ-
ing diarrhea, nausea, cramps, tenesmus, urgency, mucus
discharge, and minor bleeding will develop in up to 20%
of patients necessitating an interruption in treatment [17].
Grossly, radiation proctitis is an inﬂammatory process of the
rectal mucosa that appears edematous, beefy red, and may
have ulceration or sloughing. Microscopically, there is a loss
or distortion of the microvillus architecture with hyperemia,
edema, and ulceration [2]. Colonoscopic biopsy of the
inﬂammatory rectal mucosa is usually not recommended
due to the increased risk of bleeding and ﬁstula formation.
Acuteradiation proctitis does not increase the risk of chronic
radiation proctitis [2] and is usually self-limiting with the
discontinuation of the radiation therapy.
Table 1
Grade Symptoms or signs Overall management
0 No symptoms None
1
Occasional urgency and
occasional pain; superﬁcial
ulceration <1cm 2, occult
bleeding, and mild stricture
Outpatient
management; no lifestyle
adjustments
2
Intermittent urgency and
intermittent pain; superﬁcial
ulceration >1cm 2,
occasional bleeding, and
moderate stricture
Outpatient
management; some
lifestyle adjustments
3
Persistent urgency and
persistent pain; deep
ulceration, persistent
bleeding, severe stricture
Possible short hospital
admission or minor
surgical intervention;
major lifestyle
adjustments
4
Refractory urgency and
uncontrollable pain; gross
hemorrhage, perforation,
ﬁstula, complete obstruction
Long-term hospital
admission or major
surgical intervention
5 Sepsis, multiorgan failure,
and death Fatal complications
3. Chronic Proctitis
The time frame of chronic radiation proctitis can begin
early, even during the acute phase of radiation proctitis, but
symptoms may not become apparent until months to years
later after the cessation of therapy (median 8–12 months
after the completion of therapy) [2]. Symptoms of chronic
proctitis may include those of acute radiation proctitis but
may further include severe bleeding, strictures, perforation,
ﬁstula, and bowel obstruction. The pathological process is
diﬀerent from the acute phase and ultimately involves the
compromise of blood supply to the rectal wall which results
in full-thickness ischemia and ﬁbrotic changes [2]. Grossly,
the intestines are pale, noncompliant with telangiectasias,
and may have strictures, ulcerations, ﬁstulas, or heavy
bleeding [18]. Microscopically, there is focal distortion and
destruction of small arteries and arterioles with intimal
ﬁbrosis [18]. Chronic radiation proctitis has a signiﬁcantly
larger eﬀect on the quality of life of individuals aﬄicted
by this complication when compared to patients with acute
proctitis [2].
The incidence of chronic radiation proctitis is estimated
at 2%–20% [18]. Tissue biopsies are usually inconclusive
with an inﬂammatory picture, and a diagnosis is made
only after the exclusion of coexisting disease [2]. Since an
alteration of blood supply, especially of small vessels, is a
signiﬁcant part of chronic radiation proctitis, conditions
that further aﬀect microvascular circulation such as diabetes
and peripheral vascular disease may increase the risk of
developing proctitis [9, 10]. Another mechanism that may
have some contribution to the development of chronic
radiation proctitis is oxidative stress; antioxidant agents are
being utilized more recently to protect tissue damage in
radiation injury [19]. Furthermore, it appears that patientsGastroenterology Research and Practice 3
with inﬂammatory bowel disease (IBD) may be at an
increased risk of developing radiation proctitis as well as
other complications from external beam irradiation [20].
A retrospective study by Willet, which included 28 patients
with IBD, showed an overall incidence rate of complications
of 46% at 32 months. The incident rate is higher than pre-
vious studies of patients without IBD and may be attributed
partly to the inherent propensity of these patients to develop
bowelcomplicationsaswellastheirimmunosuppressedstate
from IBD steroid treatment [20] .T h e r ei ss o m es u g g e s t i o n
that limiting the exposure of already immunocompromised
bowel, which is possible with the use of brachytherapy, may
decrease the incidence of complications in patients with IBD
[21].
While treatment and followup for HIV has improved
to the point where it can now be considered a chronic
condition, a number of HIV/AIDS associated malignancies
havebeenrising.Someofthesemalignanciesincludecervical
cancer,analcancer,andlymphomas,allofwhichmayrequire
radiation therapy that can aﬀect the rectum. There have been
a number of reports suggesting higher complication rates in
AIDSpatientsafterradiationtherapy.Theetiologyisunclear,
but it has been suggested that the systemic glutathione
deﬁciency seen in HIV patients leads to the depletion of ra-
dioprotective thiols and increased oxidative injury. For HIV
positive patients with anal cancer and CD4 counts less than
200, Hoﬀman et al. [22] reports increased toxicity (bleeding,
and mucositis) and decreased tolerance, thereby suggesting
the need for lower treatment doses. Other studies suggest a
similartoxicityproﬁle[23]andrecommendnochangeinthe
treatmentdose.Atthistime,therearenoreportedconclusive
data on radiation proctitis in patients with HIV/AIDS and
prostate cancer.
4.Diagnosis
Radiation proctitis should be suspected in any patient who
has had pelvic radiation exposure and presents with the
symptoms mentioned above. The majority are diagnosed
after colonoscopy or sigmoidoscopy with features dem-
onstrating pallor, friability, and telangiectasias. Other causes
usually need to be excluded such as infection or inﬂamma-
tory bowel disease. Fistulizing disease including rectovaginal,
rectourethral, and rectovesicular ﬁstulas could be late pre-
senting symptoms of radiation proctitis but usually will be
preceded by other symptoms.
5. PreventativeMeasures
Although modiﬁcations of radiation techniques and doses
are continually being studied to decrease the incidence of
radiation proctitis, trials investigating preventive methods
have been disappointing to date. Small double-blind ran-
domized control trials have shown no diﬀerence in the rates
or severity of chronic radiation proctitis with the use of
rectal (200µg) misoprostol and oral (3gm b.i.d.) or rectal
(3gm daily) sucralfate [24–27]. Amifostine administered
intravenously (340mg/m2 daily) has shown some promise
in small trials in preventing symptoms of acute proctitis as
well as decreasing the severity of chronic proctitis symptoms.
The follow-up period, however, was relatively short [28–30].
Overall, preventative measures have not made a signiﬁcant
contribution to decrease the incidence of radiation proctitis.
6. Treatments
6.1. Acute Proctitis. While acute proctitis is self-limiting, up
to 20% of patients undergoing external beam radiation will
require short interruptions in their treatments to improve
symptoms. Supportive medical management is usually the
only treatment required and includes hydration, antidiar-
rheals, and possibly steroid or 5-aminosalicylate enemas.
Cessation of therapy is usually the deﬁnitive treatment and
surgical interventions are rarely needed.
6.2. Chronic Proctitis. The management of chronic proc-
titis can be divided into noninvasive treatments (anti-in-
ﬂammatory agents, sucralfate, short-chain fatty acids, hyper-
baric, antioxidants) and invasive treatments (ablation and
surgery). Although there is considerable variation in the
management strategies for chronic proctitis, there is gener-
ally a strategy of using the least invasive interventions ﬁrst
with gradual progression as symptoms and signs worsen
(Figure 1).
6.3.NoninvasiveTreatments. Noninvasive therapyforchron-
ic radiation proctitis begins with the use of oral, rectal, or
gaseous agents. These agents consist of nonsteroidal anti-
inﬂammatory drugs, sucralfate, short-chain fatty acids
(SCFA), hyperbaric oxygen (HBO), and antioxidants.
6.3.1. Anti-Inﬂammatory Agents. Anti-inﬂammatory agents
such as sulfasalazine or 5-aminosalicylic acid (mesalamine)
are usually ﬁrst line treatments, but they have low eﬃcacy
even in combination with other agents such as steroids and
antibiotics. The mechanism of action of both nonsteroidal
anti-inﬂammatory agents listed above is thought to be
through the inhibition of prostaglandin synthesis or via
the lipoxygenase pathway of arachidonic acid metabolism
[31]. Other suggested eﬀects include the inhibition of folate-
dependent enzymes and free radical scavenging activity [31].
Sulfasalazineis re-excretedin thebile afterabsorption via the
small bowel and split into sulfapyridine and 5-aminosalicylic
acid by colonic bacteria [32]. Studies have suggested that 5-
aminosalicylic acid is the active metabolite of sulfasalazine
[33]. A single randomized controlled trial by Kochhar et
al. [34] comparing sulfasalazine (500mg t.i.d) with rectal
steroids (prednisolone 20mg b.i.d.) to rectal sucralfate (2gm
b.i.d.)hadaclinicalimprovementin53%(8of15)ofpatients
with oral sulfasalazine plus rectal steroids compared to a
94% (16 of 17) improvement with rectal sucralfate alone.
Objective data from this study showed 47% (7 of 15) had
improved endoscopic ﬁnding in the sulfasalazine plus rectal
steroids group as compared to 71% (12 of 17) in the rectal4 Gastroenterology Research and Practice
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sucralfate alone [34]. This study was limited by a very small
sample size with a short followup of only 4 weeks.
Other anti-inﬂammatory agents that are used in com-
bination with sulfasalazine or 5-aminosalicylic acid include
prednisone, betamethasone, hydrocortisone, and metron-
idazole. Steroids have multiple mechanisms of action that
produce anti-inﬂammatory eﬀects which extend from sta-
bilization of lysosomes in neutrophils to prevent degran-
ulation to upregulation of anti-inﬂammatory genes via
binding to glucocorticoid receptors [35]. Metronidazole is a
nitroimidazole whose complete mechanism of action has not
been fully elucidated, but thought to be via the reduction
of the nitro group in an anaerobic environment [36]. A
study by Denton et al. [2] comparing rectal betamethasone
(5mgb.i.d.)torectalhydrocortisone(90mgb.i.d.)suggested
that the later agent had improved control. The response,
however, occurred only over the short follow-up period of
4 weeks. Another study by Cavcic et al. [37] compared the
combination of oral metronidazole (400mg daily × 3 days),
mesalamine (1gm daily × 3 days), and rectal betamethasone
to oral mesalamine and rectal betamethasone. This study
suggested that metronidazole may have synergistic eﬀects
with steroids in treating the symptoms of chronic proctitis.
Both of the above-mentioned studies suﬀer from small
sample sizes and short follow-up times which detract from
any signiﬁcant conclusions.
A newer chlorite-based anti-inﬂammatory agent which
contains the active ingredient OXO-K993 and is adminis-
tered intravenously, WF10, has recently been studied for
the treatment of radiation-induced proctitis. It was initially
developed as an adjunctive therapy for AIDS and was used in
combination with antiretroviral and opportunistic infection
prophylaxisregimens[2].Itsmechanismofactionisbelieved
to be through the modulation of the cell-mediated immune
system by stimulating phagocytosis and downregulating
antigen presentation to decrease immune activation [38]. It
has been used for radiation-induced cystitis, proctitis, and
mucositis only in Europe. Preliminary studies demonstrate
that control of bleeding symptoms for years (median follow-
up time 55 months) was obtained after two doses (0.5mL/kg
body weight per day); maintenance of eﬀective results was
achieved with repeat treatment 1-2 times per year [38]. This
anti-inﬂammatory agent has not been approved by the FDA
for use in the United States.
6.3.2. Sucralfate. Persistent symptoms after treatment with
anti-inﬂammatory agents such as 5-ASA for greater than
ﬁve months necessitates treatment with sucralfate or pen-
tosan polysulphate (PPS). Sucralfate is a highly sulphated
polyanionic disaccharide (complex of sulfated sucrose and
aluminum hydroxide) [39] that is thought to stimulate
epithelial healing and the formation of a protective barrier
[40]. A few reports, including a randomized placebo con-
trolled study, showed beneﬁts to both clinical and mucosal
outcomes with rectal sucralfate (2gm b.i.d.) [15]. Rectal
sucralfate (3gm) has also been shown to be superior to
anti-inﬂammatory regimens in treating radiation proctitis
[41] and can result in symptom relief in 75% of patients
[21]. Pentosan polysulphate (PPS, a synthetic derivative
of a glycosaminoglycan which is present in the surface ofGastroenterology Research and Practice 5
the bladder, vessels, and the gastrointestinal tract lining) is
thought to reduce epithelial permeability and prevent ad-
herence similar to sucralfate [42].
6.3.3. SCFA. Short chain fatty acids (SCFA) are the main
oxidative fuel of the colonic mucosa and also serve to stim-
ulate colonic mucosal proliferation [43]. They are thought
to be produced by the anaerobic bacteria of the colon from
nonabsorbed carbohydrates. The most signiﬁcant product of
SCFA is butyric acid [44]. SCFA also exerts a vasodilatory
eﬀect on the arteriole walls to improve blood ﬂow [45].
Radiation-induced injury results in ischemia and loss of
microvillus architecture which may result in the impairment
of SCFA absorption, thereby contributing to the changes
seen with chronic radiation proctitis [3]. Supplementation
with SFCA enemas may accelerate healing by improving the
deﬁciency experienced by the colonocytes. Two randomized
studies looked at butyrate enemas (40mM butyrate) and
found nonsigniﬁcant improvement in symptoms and signs
contrary to case reports suggesting some beneﬁt. Both stud-
ies, however, were severely underpowered [46–48]. Further
studiesarenecessarytoevaluatethepossiblebeneﬁtsofSCFA
for chronic proctitis.
6.3.4. HBO. Hyperbaric oxygen therapy (HBO) stems from
the pathological process of ischemia involving the compro-
mise of blood ﬂow to the rectal wall. The beneﬁt of HBO is
theoreticallyachievedthroughthedecreaseoftissuehypoxia,
possibly through its angiogenic and antibacterial eﬀects [49,
50]. Data on the use of HBO in chronic radiation proctitis is
limited. A review by Bennett et al. [51] found an increased
chance of improvement with hyperbaric oxygen treatment
(RR 1.75, number needed to treat = 5). However, the
degree of beneﬁt, the cumulative eﬀects, or duration of the
response cannot be quantiﬁed because of the methodology
and quality of the data. One randomized-controlled trial by
Clarke compared patients treated with 90 minutes of 100%
oxygen at 2 atmospheres with patients treated for 90 minutes
with 21% oxygen at approximately 1 atmosphere. Results
suggested some beneﬁt with symptom improvement after
30 treatments [52]. Most studies demonstrate that HBO is
expensive and not readily available in most areas except in
highlyspecializedcentersduetotherequirementformultiple
treatments and specialized equipment.
6.3.5. Antioxidants. Oxidative stress is thought to be a
major mechanism in the development of chronic radiation
proctitis; agents with antioxidant properties have been used
in an attempt to limit tissue damage in radiation injury. In
a study by Kennedy et al., which only included 10 patients,
the use of Vitamin E and C signiﬁcantly decreased the rate
of diarrhea and urgency [19]. The beneﬁt of Vitamin A
has been looked at by itself and in combination with other
therapies. In a double-blind study by Ehrenpreis, the use
of Vitamin A signiﬁcantly reduced proctitis symptoms and
the eﬀects extended to patients in the placebo group after
crossover [53]. Patel reported that the addition of Vitamin
A to treatment with 8% formalin increased the success
rate of formalin and shortened the time needed to achieve
improvement [54].
6.4. Invasive Treatments
6.4.1. Ablative Procedures. Ablative techniques are reserved
for the treatment of symptoms refractory to medical man-
agement and include formalin, endoscopic coagulation, and
argonplasma coagulation. These techniques can be associ-
ated with complications that include bleeding, perforation,
ﬁstulas, and stenosis.
6.4.2.Formalin. Inradiationproctitis,vasculartelangiectasia
and nonhealing mucosal ulceration, perhaps due to an
underlying obliterative arteritis, may lead to severe recurrent
hemorrhage. While there are no prospective studies of
formalin treatment, formalin is considered to be a safe and
eﬀective way to treat radiation proctitis causing signiﬁcant
bleeding. Formalin scleroses and seals fragile neovasculature
in radiation damaged tissues to prevent further bleeding
through chemical cauterization [16, 55, 56]. Two methods
of formalin application have been described since its ﬁrst
reported use in 1986 which are the rectal instillation of 4%
formalin solution or direct topical application of a 10%
formalinsolution[55].Thetopicalapplicationdirectlytothe
mucosa is thought to produce a more targeted local chemical
cauterization; however, its success is entirely dependent on
accurate localization. Topical formalin (10% formaldehyde
solution) is generally applied through a rigid proctoscope,
ﬂexible endoscope, or by direct application with formalin
soaked gauze [2, 57, 58] Contact with formalin for 2-3
minutes (until slight blanching of the mucosa is achieved)
is allowed and believed to cause chemical cauterization.
It is a procedure that can be performed in the oﬃce or
proceduresuitewithreportedsuccessratesof70%–80%with
few patients requiring repeat application [55]. A few studies
reported similar eﬃcacy and a better complication proﬁle
withlowerdosesofformalin(downto4%solution)[56],but
only a few patients were examined. The perianal skin needs
to be protected during the procedure to prevent stricture
and skin damage. To prevent topical damage, ﬂushing and
irrigation through ﬂexible endoscope has been proposed as
a way of administration. Formalin application is generally
safe, but bleeding, strictures, and ﬁstulas have been reported.
Direct injection of formalin allows for the more precise
administration of treatment and potentially fewer strictures,
but it is not feasible with large mucosal areas eﬀected and
could lead to ﬁstula formation. Minor side eﬀects were not
frequently reported. The duration of the treatment eﬀects
cannotbeassessedreliablyfromthedataavailablebutappear
to last a minimum of 3 months. The absence of quality of life
data means the impact of this treatment from the patient’s
perspective cannot be addressed.
6.4.3. Endoscopic Coagulation. A variety of endoscopic coag-
ulation devices are eﬀective for the control of radiation-
induced bleeding through coagulation of focal bleeding
telangiectasias. Most of the studies currently available are6 Gastroenterology Research and Practice
retrospective and show an improvement of symptoms and
a decreased recurrence after treatment with YAG laser coag-
ulation or argon plasma coagulation [2]. Both methods are
based on the delivery of thermal coagulation and should be
reserved for patients suﬀering from signiﬁcant hemorrhagic
proctitis [59]. Several treatment sessions are often required.
Argon plasma coagulation uses high-frequency energy
(monopolar diathermy) transmitted to the tissue through
an ionized gas in a noncontact fashion [59]. Its ability to
control bleeding throughout the gastrointestinal tract has
been demonstrated, and it has very limited tissue pene-
tration, making it attractive for treatment of superﬁcial
bleeding. Available studies are retrospective and have a small
number of patients [60, 61]. However, all studies have
shown higher hemoglobin and fewer symptoms in patients
with hemorrhagic proctitis who failed medical therapy.
Single sessions have been reported to signiﬁcantly improve
symptoms [62], but on average, two to three treatments
are needed to achieve this result. Improvements persisted
for a number of months after therapy was ﬁnished [2, 63].
Most of the complications reported were mild and included
cramps, mucus discharge, and stricture [2]. However, signif-
icant complications including large ulcers, perforations, and
rectourethral and rectovaginal ﬁstulas have been reported.
YAG lasers have the same theoretical beneﬁt as argon
plasma coagulation with a limited depth of penetration and
the possibility for precise application. Evidence for their use
is similar to those for argon plasma coagulation with only
a few studies available, including those with fewer than 10
patients. [64, 65]. Based on studies currently available, YAG
lasers may be useful in the treatment of radiation proctitis,
but the data are not strong enough to support their wide use.
For both argon plasma coagulation and YAG lasers, cost and
availability may also present signiﬁcant obstacles.
6.4.4. Surgery. Although surgery is often necessary for a
diagnosis of radiation proctitis and as an adjunct to some of
the treatment options described above, it is considered a last
resort for patients with radiation proctitis. Fewer than 10%
[66] of patients ultimately require surgery. When required,
it is directed at speciﬁc symptoms and complications of
radiation proctitis such as intractable bleeding, perforation,
strictures, and ﬁstulas. Rarely, surgery has been used to treat
uncontrollablepain.Gasandstoolincontinencearecommon
symptoms that often accompany these complications and
should be considered when deciding on the need for sur-
gical intervention. When surgery is being considered, the
pathophysiology of radiation damage must be taken into
account. Microvascular damage caused by radiation not only
causes the symptoms of radiation proctitis, but also can
signiﬁcantly impair healing after any surgery. Fecal diversion
with either a colostomy or ileostomy is a common rea-
son patients are referred to surgeons. Diverting the stool
stream decreases symptoms of pain, tenesmus, drainage, and
infection but rarely eliminates them completely. An ostomy
can also improve symptoms related to incontinence and
stricture, but it has a limited eﬀect on bleeding. At least
one study [67] showed signiﬁcant improvement in bleeding
fromadivertingloopcolostomybutnotcompleteresolution.
Diversion will improve symptoms but without additional in-
terventions, the improvements in symptoms are unlikely to
persist after an ostomy reversal.
Rectourethral, rectovaginal and rectovesicular ﬁstulas
present with infections, pain, or incontinence symptoms and
are one of the more common complications of proctitis.
Surgical treatment options have traditionally included local
excision and reconstruction such as an advancement ﬂap.
Due to poorly vascularized tissues and low healing rates,
however, these interventions should not be used as the
only treatment modalities. Additional options to improve
success of ﬁstula repairs include pedunculated ﬂaps, such
as a gracilis or martius ﬂap, which are used to facilitate
healing by introducing well-vascularized healthy tissue.
Diversion of stool or the urinary stream with an ostomy
or a suprapubic catheter should be considered in almost all
cases where repair is attempted. In some patients, a complete
diversion will improve symptoms and their quality of life to
the point that they do not require any further intervention
[66, 68–70] even though the underlying problem is not
repaired. In cases of complicated ﬁstulous disease, especially
when accompanied by signiﬁcant pain and incontinence,
a proctectomy or pelvic exenteration with or without re-
constructionisrecommended.Whilethisisadeﬁnitivetreat-
ment, it is accompanied by signiﬁcant morbidity, including
exceedingly high rates of anastomotic leaks in cases of
reconstruction and high rates of perineal wound complica-
tions when reconstruction is not attempted [69, 70]. When
considering reconstruction for these patients, a temporary
diversion should be part of the initial operation. It is also
important to discuss with patients that although these
procedures may be a technical success, they often result
in unacceptable long-term morbidity including complicated
scarring, stricture, and incontinence. In cases of abdominal
perineal resections, bringing a well-vascularized tissue to
closethewound,suchasrectusabdominus,gracilisorgluteal
V-Y ﬂap, will signiﬁcantly decrease rates of postoperative
wound complications.
In cases of severe and intractable bleeding, surgical op-
tions are very limited, because a diversion will rarely control
the bleeding completely. Diverting loop colostomy was de-
scribed in one study as a successful way of controlling
bleeding [67], but in many instances, proctectomy may be
the only option available. When strictures are an issue, a
diversion of the stool stream will often result in a signiﬁcant
improvement of symptoms. Other options include resection
with reconstruction when the stricture is higher in the
rectum or an advancement ﬂap (mucosa or skin) when the
rectal stricture is in the anus. In all cases, given the poor
qualityofthetissues,atleastatemporarydiversionshouldbe
considered. When surgical treatment is needed, most studies
demonstrate poor outcomes with high complication rates
(15%–80%), and a mortality of 3%–9% [66, 68–70].
7. Conclusion
Radiation proctitis is a relatively rare complication of radia-
tion therapy. Rates of both acute and chronic proctitis haveGastroenterology Research and Practice 7
been decreasing with improved radiation therapy techniques
that allow for the targeted delivery of higher doses of ra-
diation. It is important to note that radiation proctitis is a
result of radiation doses that are beyond the ability of the
normaltissuetorepairorrecoverfrominjury.Thereisrecent
evidence that the impairment of the rectum’s ability to heal
may also mean that other organs exposed to the same high
radiation doses may be at increased risk of malignant trans-
formation [71]. It has been suggested that patients exposed
to higher doses of radiation may need to be more closely
screened for other malignancies [71], but further studies
needtobeconductedbeforedeﬁnitiverecommendationscan
be made. Although there are no good preventive measures
available at this point, most instances of proctitis are self-
limitedandrespondtomedicalmanagement.Acombination
of sucralfate, steroids, and pain control have been successful
in most cases to improve symptoms. In more severe cases,
especially with bleeding, chemical (formalin) or thermal
(endoscopic coagulation) treatments have been successful.
Surgery is rarely required to treat this condition, but when
performed can lead to signiﬁcant improvements. Surgery,
however, also results in the increased risk of postsurgical
complications.Morestudiesareneededtoprospectivelylook
at both the prevention and treatmentof radiation proctitis as
well as patients with special consideration such as those with
IBD and HIV/AIDS.
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